NCT01255891

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Dr. Tamim Niazi · Academic / Other
• Sex: Male
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post radical prostatectomy patients with high risk pathological features for failure. To determine the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and clinical progression rate at 5 years.

Detailed description

Same as brief Summary

Conditions

• Adenocarcinoma of the Prostate

Interventions

Type	Name	Description
RADIATION	Androgen suppression plus radiation therapy	Adjuvant androgen suppression plus radiation therapy

Timeline

• Start date: 2010-01-01
• Primary completion: 2023-08-01
• Completion: 2023-09-01
• First posted: 2010-12-08
• Last updated: 2024-12-09

Locations

2 sites across 1 country: Canada